WRW4 (trifluoroacetate salt) (Synonyms: Trp-Arg-Trp-Trp-Trp-Trp-CONH2, Trp-Arg-Trp-Trp-Trp-Trp-NH2, WRWWWW-NH2) |
Katalog-Nr.GC52457 |
A peptide antagonist of FPR2 and FPR3
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
WRW4 is a peptide antagonist of formyl peptide receptor 2 (FPR2; IC50 = 0.23 µM) and FPR3, previously known as FPR-like 1 (FPRL1) and FPRL2, respectively.1,2 It inhibits increases in intracellular calcium and chemotaxis induced by the FPR1 and FPR2 agonist WKYMVm in RBL-2H3 cells expressing FPR2 and by the FPR3 agonist F2L in isolated human monocytes when used at a concentration of 10 µM. WRW4 (10 µM) also prevents the production of superoxide induced by amyloid-β (1-42) in isolated human neutrophils.1 In vivo, WRW4 (1 mg/kg) increases lung edema and bronchoalveolar lavage fluid (BALF) protein levels in the absence and presence of the antibiotic ceftriaxone in a mouse model of acute lung injury induced by S. pneumoniae.3
1.Bae, Y.-S., Lee, H.Y., Jo, E.J., et al.Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signalingJ. Immunol.173(1)607-614(2004) 2.Shin, E.H., Lee, H.-Y., Kim, S.D., et al.Trp-Arg-Trp-Trp-Trp-Trp antagonizes formyl peptide receptor like 2-mediated signalingBiochem. Biophys. Res. Commun.341(4)1317-1322(2006) 3.Siegel, E.R., Croze, R.H., Fang, X., et al.Inhibition of the lipoxin A4 and resolvin D1 receptor impairs host response to acute lung injury caused by pneumococcal pneumonia in miceAm. J. Physiol. Lung Cell Mol. Physiol.320(6)L1085-L1092(2021)
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *